Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 131 shares at $22.50 ($3K) on 2021-12-09, disclosed to the SEC on 2021-12-13.
Scheduled sale ($3k) by VP, Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |